| Dr Joel D Smukowski, MD | |
|
3237 S 16th St, Milwaukee, WI 53215-4526 | |
| (414) 527-8728 | |
| Not Available |
| Full Name | Dr Joel D Smukowski |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 30 Years |
| Location | 3237 S 16th St, Milwaukee, Wisconsin |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1396799359 | NPI | - | NPPES |
| 32445400 | Medicaid | WI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 40052-020 (Wisconsin) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Ascension Se Wisconsin Hospital - St Joseph Campus | Milwaukee, WI | Hospital |
| Ascension St Francis Hospital | Milwaukee, WI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Emergency Medicine Specialists Sc | 8729975461 | 195 |
News Archive
Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced that the U.S. Food and Drug Administration (FDA) has determined that the "essential use" status of Combivent® (ipratropium bromide and albuterol sulfate) Inhalation Aerosol will be effective through December 31, 2013. With this ruling, COMBIVENT will remain on the market and available to the more than two million chronic obstructive pulmonary disease (COPD) patients who rely on it as a bronchodilator.
A new partnership will establish formal collaboration among genetic researchers and Clemson University faculty at the Greenwood Genetic Center and Self Regional Healthcare, expanding an already successful working relationship.
Helix BioMedix, Inc., a developer of bioactive peptides, today announced financial results for the second quarter ended June 30, 2012.
Excluding trainees, around half of the doctors working in A&E in the UK are employed in staff grade and associate specialist (SAS) positions - which are distinct from consultant posts.
› Verified 6 days ago
| Entity Name | Emergency Medicine Specialists Sc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568413524 PECOS PAC ID: 8729975461 Enrollment ID: O20040228000032 |
News Archive
Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced that the U.S. Food and Drug Administration (FDA) has determined that the "essential use" status of Combivent® (ipratropium bromide and albuterol sulfate) Inhalation Aerosol will be effective through December 31, 2013. With this ruling, COMBIVENT will remain on the market and available to the more than two million chronic obstructive pulmonary disease (COPD) patients who rely on it as a bronchodilator.
A new partnership will establish formal collaboration among genetic researchers and Clemson University faculty at the Greenwood Genetic Center and Self Regional Healthcare, expanding an already successful working relationship.
Helix BioMedix, Inc., a developer of bioactive peptides, today announced financial results for the second quarter ended June 30, 2012.
Excluding trainees, around half of the doctors working in A&E in the UK are employed in staff grade and associate specialist (SAS) positions - which are distinct from consultant posts.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Joel D Smukowski, MD 10625 W North Ave, 102, Milwaukee, WI 53226-2315 Ph: (414) 877-5350 | Dr Joel D Smukowski, MD 3237 S 16th St, Milwaukee, WI 53215-4526 Ph: (414) 527-8728 |
News Archive
Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced that the U.S. Food and Drug Administration (FDA) has determined that the "essential use" status of Combivent® (ipratropium bromide and albuterol sulfate) Inhalation Aerosol will be effective through December 31, 2013. With this ruling, COMBIVENT will remain on the market and available to the more than two million chronic obstructive pulmonary disease (COPD) patients who rely on it as a bronchodilator.
A new partnership will establish formal collaboration among genetic researchers and Clemson University faculty at the Greenwood Genetic Center and Self Regional Healthcare, expanding an already successful working relationship.
Helix BioMedix, Inc., a developer of bioactive peptides, today announced financial results for the second quarter ended June 30, 2012.
Excluding trainees, around half of the doctors working in A&E in the UK are employed in staff grade and associate specialist (SAS) positions - which are distinct from consultant posts.
› Verified 6 days ago
Dr. Colleen Ann Crowe, M.D., M.P.H. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 9200 W Wisconsin Ave, Milwaukee, WI 53226 Phone: 414-805-6469 | |
Natalia Rumas, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2323 N Lake Dr, Milwaukee, WI 53211 Phone: 414-290-6720 Fax: 414-290-6755 | |
Adam C Ankrum, D.O. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 111 E Wisconsin Ave, Suite 2000, Milwaukee, WI 53202 Phone: 414-290-6720 Fax: 414-290-6755 | |
Andrea Michelle Kraus, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 3237 S 16th St Ste 100, Milwaukee, WI 53215 Phone: 414-647-5203 Fax: 414-858-2236 | |
Lisa Hubbard, CFNP Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 5000 W Chambers St, Milwaukee, WI 53210 Phone: 414-447-2000 Fax: 414-874-4393 | |
Mr. Brad A. Johnson, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2900 W Oklahoma Ave, Milwaukee, WI 53215 Phone: 414-649-6000 | |
Mckenna Jean Knych, Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 9200 W Wisconsin Ave, Milwaukee, WI 53226 Phone: 414-805-6450 Fax: 414-805-6464 |